Skip to main content
Clinical Trials/NCT05929144
NCT05929144RecruitingNot Applicable

Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases at Inserm U1237 NeuroPresage Team, Cyceron Center in Caen

University Hospital, Caen1 site in 1 country40 target enrollmentStarted: May 5, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
40
Locations
1
Primary Endpoint
Optimization of MRI sequences

Study Overview

Brief Summary

The Inserm NeuroPresage team has been using MRI for more than 20 years in the study of normal ageing and memory pathologies to further the understanding and the characterization of early diagnosis and the cerebral substrates of cognitive deficits in patients, particularly in the context of neurodegenerative diseases.

Two years ago, a new 3T MRI camera was installed at the Cyceron centre. It is more efficient and should make it possible to obtain better quality images and/or to reduce the time required to acquire these images.

In this context, it seems important to test the different sequences that we classically use in our studies, or that we plan to implement in our next studies (learning and text retrieval fMRI task), in order to optimize them, with a view to integrating them in our future studies.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Healthy volunteers of legal age
  • •Affiliation with a social security scheme or beneficiary of such a scheme
  • •Signing of the protocol informed consent
  • •For women of childbearing age or capacity, a urine pregnancy test before inclusion

Exclusion Criteria

  • •Protected persons in accordance with articles L. 1121-5 to L.1121-8 of the Public Health Code: protected adults, pregnant and nursing women
  • •Presence of contraindications to MRI examination without contrast agents injection
  • •Presence of a chronic neurological or psychiatric condition (including substance use disorder)
  • •History of brain disease (vascular, degenerative, malformative, tumour, or head trauma with loss of consciousness for more than one hour)
  • •Current or recent use of medications that may interfere with imaging (psychotropic drugs, antihistamines with anticholinergic action, antiparkinsonian drugs, benzodiazepines including muscle relaxants, long-term steroidal anti-inflammatory drugs, antiepileptic drugs, central painkillers)

Arms & Interventions

Healthy volunteers

Other

Intervention: MRI sequences testing (Other)

Outcomes

Primary Outcomes

Optimization of MRI sequences

Time Frame: During MRI sessions

TR, TE, Flip Angle, asset phase, asset slice parameters

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials